Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture

Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture Drug Approval Package: Evenity U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Evenity Company: Amgen Inc. Application Number: 761062 Approval Date: 04/09/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2019 FDA - Drug Approval Package

2. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. (PubMed)

Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Optimal long-term osteoporosis drug treatment (ODT) is uncertain.To summarize the effects of long-term ODT and ODT discontinuation and holidays.Electronic bibliographic databases (January 1995 to October 2018) and systematic review bibliographies.48 studies that enrolled men or postmenopausal women aged 50 years or older who were being investigated or treated for fracture (...) prevention, compared long-term ODT (>3 years) versus control or ODT continuation versus discontinuation, reported incident fractures (for trials) or harms (for trials and observational studies), and had low or medium risk of bias (ROB).Two reviewers independently rated ROB and strength of evidence (SOE). One extracted data; another verified accuracy.Thirty-five trials (9 unique studies) and 13 observational studies (11 unique studies) had low or medium ROB. In women with osteoporosis, 4 years

Full Text available with Trip Pro

2019 Annals of Internal Medicine

3. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may

2019 NIHR Dissemination Centre

4. Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain

Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Discover Portal Discover Portal Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Published on 13 December 2016 doi: Injecting cement into osteoporotic spinal fractures within six weeks reduces pain in the first few months and disability six (...) centres. Share your views on the research. Why was this study needed? Worldwide, an estimated 1.4 million people with osteoporosis experience vertebral fractures. Most osteoporotic vertebral fractures are treated conservatively with painkillers, bed rest and mobility exercises as function improves. However, painkillers and prolonged bed rest can both have adverse effects in older people. Vertebroplasty involves injecting special cement into the broken vertebrae to relieve pain and strengthen the bone

2019 NIHR Dissemination Centre

5. Prompts for GPs may improve diagnosis and treatment of osteoporosis

Prompts for GPs may improve diagnosis and treatment of osteoporosis Prompts for GPs may improve diagnosis and treatment of osteoporosis Discover Portal Discover Portal Prompts for GPs may improve diagnosis and treatment of osteoporosis Published on 30 August 2016 doi: Prompts for GPs with education and reminders for patients may improve “guideline consistent behaviour” and diagnosis and treatment of osteoporosis. Similar techniques aimed at improving GP management of other common (...) benefit more. Share your views on the research. Why was this study needed? Musculoskeletal conditions such as osteoporosis, back pain and arthritis are common causes of pain and disability in the UK. One in six adults lives with a chronic musculoskeletal condition. Every year, over 20% of people consult their GP about musculoskeletal problems. Musculoskeletal conditions are a major cause of health system spending. In 2009-10, the NHS spent £4.76 billion in this area; this is more than £13 million

2019 NIHR Dissemination Centre

6. Osteoporosis. (PubMed)

Osteoporosis. Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used (...) in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high

2019 Lancet

7. The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper

The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper - Hill - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term (...) The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper Department of Haematology, Leeds Teaching Hospitals, Leeds, UK Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK Faculty

Full Text available with Trip Pro

2019 British Committee for Standards in Haematology

8. Fracture risk reduction by anti-osteoporosis pharmacotherapy according to baseline fracture risk among post-menopausal women (protocol for a systematic review and meta-analysis of randomised trials)

Fracture risk reduction by anti-osteoporosis pharmacotherapy according to baseline fracture risk among post-menopausal women (protocol for a systematic review and meta-analysis of randomised trials) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

9. Moxibustion in primary osteoporosis: a systematic review and meta-analysis

Moxibustion in primary osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

10. Acupuncture for postmenopausal osteoporosis: a systematic review protocol

Acupuncture for postmenopausal osteoporosis: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

11. A systematic review and environmental scan of decision aids for osteoporosis: a review protocol

A systematic review and environmental scan of decision aids for osteoporosis: a review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

12. Effect of teriparatide and bisphosphonate on new fractures in postmenopausal woman with osteoporosis: systematic review and mate analysis

Effect of teriparatide and bisphosphonate on new fractures in postmenopausal woman with osteoporosis: systematic review and mate analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

13. Effect of Pulsed Electromagnetic Field on bone related outcomes in experimental rodents of Osteoporosis : a systematic review

Effect of Pulsed Electromagnetic Field on bone related outcomes in experimental rodents of Osteoporosis : a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

14. Liuwei dihuang decoction for primary osteoporosis: a protocol for a systematic review and meta-analysis

Liuwei dihuang decoction for primary osteoporosis: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

15. A systemic review and network meta-analysis of the efficacy and safety of bisphosphonates and RANKL inhibitors for the treatment of glucocorticoid-induced osteoporosis

A systemic review and network meta-analysis of the efficacy and safety of bisphosphonates and RANKL inhibitors for the treatment of glucocorticoid-induced osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

16. The methodological quality of guideline recommendations on vitamin D and calcium intakes: a systematic review of food-based dietary guidelines and osteoporosis prevention guidelines

The methodological quality of guideline recommendations on vitamin D and calcium intakes: a systematic review of food-based dietary guidelines and osteoporosis prevention guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

17. The efficacy and safety of isoflavone treatment in post-menopausal women with osteoporosis: a systematic review and meta-analysis

The efficacy and safety of isoflavone treatment in post-menopausal women with osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

18. Romosozumab for the treatment of osteoporosis: a systematic review and meta-analysis

Romosozumab for the treatment of osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

19. Bisphosphonates for older adults with primary osteopenia or osteoporosis: a bayesian network meta-analysis

Bisphosphonates for older adults with primary osteopenia or osteoporosis: a bayesian network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

20. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO